Recce Pharma's R327 Defeats Multidrug-Resistant Superbug
Recce's R327 eradicates multidrug-resistant Acinetobacter baumannii, outperforming ciprofloxacin.
Recce Pharmaceuticals Ltd. has reported promising outcomes from a study indicating that its drug, RECCE 327 (R327), effectively eradicates the multidrug-resistant 'superbug' Acinetobacter baumannii. The research demonstrated that R327 achieved a reduction in bacterial presence by over 99.99999% within one hour of administration and sustained its effectiveness for 24 hours, surpassing the performance of the conventional antibiotic ciprofloxacin. These results highlight R327's potential as a robust treatment option for severe infections, including those resistant to multiple drugs.
My international experience as a researcher in Taiwan for three years has equipped me with a global perspective, enabling me to create content that resonates with an international audience.
Más de Pharma News
Todos los artículos →
Ab Science revisa los cronogramas de los ensayos tras tres inspecciones GCP
Novo Nordisk firma un acuerdo de $2.6B con Hengrui por un GLP-1 oral
Discussion